Literature DB >> 34799733

Discovering new biology with drug-resistance alleles.

Allyson M Freedy1,2, Brian B Liau3,4.   

Abstract

Small molecule drugs form the backbone of modern medicine's therapeutic arsenal. Often less appreciated is the role that small molecules have had in advancing basic biology. In this Review, we highlight how resistance mutations have unlocked the potential of small molecule chemical probes to discover new biology. We describe key instances in which resistance mutations and related genetic variants yielded foundational biological insight and categorize these examples on the basis of their role in the discovery of novel molecular mechanisms, protein allostery, physiology and cell signaling. Next, we suggest ways in which emerging technologies can be leveraged to systematically introduce and characterize resistance mutations to catalyze basic biology research and drug discovery. By recognizing how resistance mutations have propelled biological discovery, we can better harness new technologies and maximize the potential of small molecules to advance our understanding of biology and improve human health.
© 2021. Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34799733      PMCID: PMC9530778          DOI: 10.1038/s41589-021-00865-9

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   16.174


  95 in total

1.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors:  S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

3.  Selective degradation of splicing factor CAPERα by anticancer sulfonamides.

Authors:  Taisuke Uehara; Yukinori Minoshima; Koji Sagane; Naoko Hata Sugi; Kaoru Ogawa Mitsuhashi; Noboru Yamamoto; Hiroshi Kamiyama; Kentaro Takahashi; Yoshihiko Kotake; Mai Uesugi; Akira Yokoi; Atsushi Inoue; Taku Yoshida; Miyuki Mabuchi; Akito Tanaka; Takashi Owa
Journal:  Nat Chem Biol       Date:  2017-04-24       Impact factor: 15.040

Review 4.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369

5.  Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.

Authors:  Jasper Edgar Neggers; Bert Kwanten; Tim Dierckx; Hiroki Noguchi; Arnout Voet; Lotte Bral; Kristien Minner; Bob Massant; Nicolas Kint; Michel Delforge; Thomas Vercruysse; Erkan Baloglu; William Senapedis; Maarten Jacquemyn; Dirk Daelemans
Journal:  Nat Commun       Date:  2018-02-05       Impact factor: 14.919

6.  Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.

Authors:  Alba Maiques-Diaz; Gary J Spencer; James T Lynch; Filippo Ciceri; Emma L Williams; Fabio M R Amaral; Daniel H Wiseman; William J Harris; Yaoyong Li; Sudhakar Sahoo; James R Hitchin; Daniel P Mould; Emma E Fairweather; Bohdan Waszkowycz; Allan M Jordan; Duncan L Smith; Tim C P Somervaille
Journal:  Cell Rep       Date:  2018-03-27       Impact factor: 9.423

7.  Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.

Authors:  Christos Adamopoulos; Tamer A Ahmed; Maxwell R Tucker; Peter M U Ung; Min Xiao; Zoi Karoulia; Angelo Amabile; Xuewei Wu; Stuart A Aaronson; Celina Ang; Vito W Rebecca; Brian D Brown; Avner Schlessinger; Meenhard Herlyn; Qi Wang; David E Shaw; Poulikos I Poulikakos
Journal:  Cancer Discov       Date:  2021-02-10       Impact factor: 39.397

8.  The mechanism of action of colchicine. Binding of colchincine-3H to cellular protein.

Authors:  G G Borisy; E W Taylor
Journal:  J Cell Biol       Date:  1967-08       Impact factor: 10.539

9.  Inhibitors of BRAF dimers using an allosteric site.

Authors:  Xiomaris M Cotto-Rios; Bogos Agianian; Nadege Gitego; Emmanouil Zacharioudakis; Orsi Giricz; Yang Wu; Yiyu Zou; Amit Verma; Poulikos I Poulikakos; Evripidis Gavathiotis
Journal:  Nat Commun       Date:  2020-09-01       Impact factor: 14.919

10.  Mutational processes shape the landscape of TP53 mutations in human cancer.

Authors:  Andrew O Giacomelli; Xiaoping Yang; Robert E Lintner; James M McFarland; Marc Duby; Jaegil Kim; Thomas P Howard; David Y Takeda; Seav Huong Ly; Eejung Kim; Hugh S Gannon; Brian Hurhula; Ted Sharpe; Amy Goodale; Briana Fritchman; Scott Steelman; Francisca Vazquez; Aviad Tsherniak; Andrew J Aguirre; John G Doench; Federica Piccioni; Charles W M Roberts; Matthew Meyerson; Gad Getz; Cory M Johannessen; David E Root; William C Hahn
Journal:  Nat Genet       Date:  2018-09-17       Impact factor: 38.330

View more
  2 in total

Review 1.  Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity.

Authors:  Matthew W Boudreau; Paul J Hergenrother
Journal:  RSC Med Chem       Date:  2022-05-09

2.  CRISPR-Suppressor Scanning Unsticks Molecular Glues.

Authors:  Stephanie A Robinson; Steven M Banik
Journal:  ACS Cent Sci       Date:  2022-03-08       Impact factor: 18.728

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.